Has been a long week and I am finally getting to d
Post# of 148177
(Total Views: 651)
Posted On: 09/07/2020 2:29:07 PM
Has been a long week and I am finally getting to digest the conference call on 09/02. No tea leaf reading required...MHRA favors Leronlimab and is expediting regulatory process to get this to their people. See conference note below on COVID/HIV:
Nader thanks shareholders for grassroots awareness
September 9th – Granted meeting teleconference with MHRA to discuss Fast Track Approval on 09/09
• August 14th – Cytodyn requests Fast Track Approval to MHRA due to CD10 topline report; EIND data; other data
• August 24th – MHRA responds to company that they are submitting request to senior management team in licensing division for further input
• August 27th – MHRA responds to request; teleconference to discuss the regulatory pathway for fast track approval for Leronlimab based on CD10 results; 1 hr teleconference to discuss the route to market for Leronlimab in UK; prior to this meeting MHRA needs summary of BLA and this meeting is equivalent to pre-BLA meeting in US. MHRA is requiring 5 business days to expedite review of the package – specifically Manufacturing, clinical and non-clinical. Amarex has finalized this package earlier today (09/02). Cytodyn will review this package and return to Amarex within 24 hrs (09/03). Package to be delivered on (09/04) thus meeting on (09/09). MHRA quickly granted meeting to Cytodyn on 09/09 upon hearing that company would submit package on (09/05).
August 12th – filed EUA w/FDA
• FDA has indicated that a decision is forthcoming
CD12 trial (Severe/Critical COVID19)
• UK ethical committee approved enrollment in CD12 study in UK
• Recommend Cytodyn resubmit CD12 trial to Urgent Public Health (UPH). If UPH deems CD12 trial urgent health issue, Cytodyn would receive extra support from enrollment site and from government.
• In US – interim results with be analyzed early part of October and will be shared with UK as well as US
FDA Type A meeting for combination HIV BLA
• FDA responds to company in writing yesterday (09/01) 3 days early and offered teleconference to ensure that your revised BLA meets our recommendations followed by 30-day review of new package.
Submitting 350 mg dose for combo HIV to UK and requesting monotherapy approval (700 mg) in UK
Nader thanks shareholders for grassroots awareness
September 9th – Granted meeting teleconference with MHRA to discuss Fast Track Approval on 09/09
• August 14th – Cytodyn requests Fast Track Approval to MHRA due to CD10 topline report; EIND data; other data
• August 24th – MHRA responds to company that they are submitting request to senior management team in licensing division for further input
• August 27th – MHRA responds to request; teleconference to discuss the regulatory pathway for fast track approval for Leronlimab based on CD10 results; 1 hr teleconference to discuss the route to market for Leronlimab in UK; prior to this meeting MHRA needs summary of BLA and this meeting is equivalent to pre-BLA meeting in US. MHRA is requiring 5 business days to expedite review of the package – specifically Manufacturing, clinical and non-clinical. Amarex has finalized this package earlier today (09/02). Cytodyn will review this package and return to Amarex within 24 hrs (09/03). Package to be delivered on (09/04) thus meeting on (09/09). MHRA quickly granted meeting to Cytodyn on 09/09 upon hearing that company would submit package on (09/05).
August 12th – filed EUA w/FDA
• FDA has indicated that a decision is forthcoming
CD12 trial (Severe/Critical COVID19)
• UK ethical committee approved enrollment in CD12 study in UK
• Recommend Cytodyn resubmit CD12 trial to Urgent Public Health (UPH). If UPH deems CD12 trial urgent health issue, Cytodyn would receive extra support from enrollment site and from government.
• In US – interim results with be analyzed early part of October and will be shared with UK as well as US
FDA Type A meeting for combination HIV BLA
• FDA responds to company in writing yesterday (09/01) 3 days early and offered teleconference to ensure that your revised BLA meets our recommendations followed by 30-day review of new package.
Submitting 350 mg dose for combo HIV to UK and requesting monotherapy approval (700 mg) in UK
(6)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼